Hyperuricemia and Diabetic Nephropathy
NCT04799925 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2021-03-16
Summary
The purpose of the study is to detect the effect of treatment of hyperuricemia on eGFR (Estimated Glomerular Filtration Rate) as an objective criterion for assessment of progression of diabetic nephropathy in patients with Type 2 Diabetes Mellitus.
Conditions
- Hyperuricemia
- Diabetic Nephropathies
Interventions
- DRUG
-
Febuxostat
uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-15
- Primary Completion
- 2022-04-15
- Completion
- 2022-12-30
More Related Trials
-
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03372200 ·Status: COMPLETED ·Phase: PHASE3
-
Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
NCT03200210 ·Status: UNKNOWN ·Phase: PHASE4
-
The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
NCT04157959 ·Status: UNKNOWN ·Phase: PHASE1
-
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
NCT01082640 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
NCT04180982 ·Status: UNKNOWN ·Phase: PHASE2
-
Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy
NCT01984749 ·Status: UNKNOWN ·Phase: NA
-
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
NCT03375632 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
NCT06859073 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy Study of Intramuscular Uricase-PEG 20
NCT01038947 ·Status: UNKNOWN ·Phase: PHASE1
-
Effect of Dotinurad in Hyperuricemia With Hypertension
NCT06834230 ·Status: RECRUITING ·Phase: PHASE4
-
Low-dose Colchicine With or Without Stepwise Dose Titration of Febuxostat for Flare Prophylaxis in Gout
NCT04697602 ·Status: TERMINATED ·Phase: NA
-
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
NCT02837198 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Intravenous Uricase-PEG 20
NCT01021241 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects
NCT07324434 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03006445 ·Status: COMPLETED ·Phase: PHASE3
-
the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
NCT02279342 ·Status: TERMINATED ·Phase: PHASE4
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02416167 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
NCT02252835 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
NCT02752633 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
NCT03316131 ·Status: COMPLETED ·Phase: PHASE2
-
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
NCT00987415 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
NCT01078389 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT02290210 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
NCT05513976 ·Status: UNKNOWN ·Phase: PHASE2
-
Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers
NCT05226013 ·Status: UNKNOWN ·Phase: PHASE1